Edwards Lifesciences Co. (NYSE:EW) Given Average Rating of "Hold" by Brokerages

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) has earned a consensus recommendation of "Hold" from the twenty-four brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $79.60.

A number of equities research analysts have issued reports on EW shares. Piper Sandler boosted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research report on Tuesday. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Truist Financial lowered their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Finally, Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at approximately $2,150,791.86. This represents a 27.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $74.91, for a total value of $447,961.80. Following the completion of the transaction, the chief executive officer now directly owns 58,284 shares of the company's stock, valued at $4,366,054.44. This represents a 9.31% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,192 shares of company stock valued at $4,709,454. Insiders own 1.29% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EW. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $26,000. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $27,000. SouthState Corp bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $27,000. Finally, Millstone Evans Group LLC bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $29,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 1.3%

Edwards Lifesciences stock traded up $1.04 during trading on Wednesday, hitting $77.92. The company's stock had a trading volume of 4,956,186 shares, compared to its average volume of 5,089,685. The stock has a market capitalization of $45.71 billion, a price-to-earnings ratio of 11.18, a P/E/G ratio of 4.82 and a beta of 1.12. The stock's fifty day moving average is $71.89 and its 200 day moving average is $71.67. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.66 earnings per share. As a group, equities research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.